NCT07093268View on ClinicalTrials.gov

Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

June 15, 2026

Study Completion Date

January 15, 2027

Conditions
Amyotrophic Lateral SclerosisMotor Neuron Disease
Interventions
DRUG

Intrathecal Riluzole

Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.

Trial Locations (2)

4575

Sunshine Coast University Hospital, Birtinya

5042

Flinders Medical Centre, Bedford Park

Sponsors

Lead Sponsor

Brain Trust Bio
All Listed Sponsors
lead

Brain Trust Bio

INDUSTRY